Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;25(7):813-824.
doi: 10.1007/s11912-023-01400-w. Epub 2023 Apr 12.

First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology

Vibor Milunović  1 , Inga Mandac Smoljanović  2   3 , Martina Bogeljić Patekar  2 , Viktor Zatezalo  2 , Marin Kursar  2 , Delfa Radić-Krišto  2   3 , Slobodanka Ostojić Kolonić  2   3 , Slavko Gašparov  3   4
Affiliations
Review

First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology

Vibor Milunović et al. Curr Oncol Rep. 2023 Jul.

Abstract

Purposeof review: The main aim of this review is to summarize first-line therapy of nodal T-cell non-Hodgkin lymphoma.

Recent findings: Current treatment with CHOP chemotherapy results in poor outcomes in the majority of patients. However, there are advances within the field. First breakthrough is the ECHELON-2 trial which showed that the addition of brentuximab vedotin improves outcomes in anaplastic large cell lymphoma. However, other types of peripheral T-cell non-Hodgkin lymphoma were underrepresented with optimal treatment not known. Second breakthrough is an increase of autologous stem cell transplantation usage in the first complete metabolic remission, except in ALK + anaplastic large cell lymphoma, offering better disease control. Despite advances in the field, CHOP remains the standard treatment for the majority of these lymphomas, but multiple trials are underway with the aim to improve this unmet need in hematology and, hopefully, leading us to a new era in the treatment of peripheral T-cell lymphomas.

Keywords: Alemtuzumab; Brentuximab vedotin; CHOP protocol; Hematopoietic stem cell transplantation; Histone deacetylase inhibitors; Peripheral T-cell lymphoma.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. https://doi.org/10.1182/blood-2016-01-643569 . - DOI - PubMed - PMC
    1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti et al. (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 36:1720–1748. https://doi.org/10.1038/s41375-022-01620-2
    1. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. https://doi.org/10.1182/blood.2022015851 . - DOI - PubMed
    1. Vega F, Amador C, Chadburn A, Hsi ED, Slack G, Medeiros LJ, et al. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Mod Pathol. 2022;35:306–18. https://doi.org/10.1038/s41379-021-00937-0 . - DOI - PubMed
    1. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240–51. https://doi.org/10.1093/jnci/92.15.1240 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources